

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Highly Specialised Technologies Evaluation

### Metreleptin for treating generalised and partial lipodystrophy [ID861]

#### Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Aegerion Pharmaceuticals Limited (metreleptin)</li> </ul> <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency</li> <li>• Children Living with Inherited Metabolic Diseases (CLIMB)</li> <li>• Contact a Family</li> <li>• Diabetes Research and Wellness Foundation</li> <li>• Diabetes UK</li> <li>• Genetic Alliance UK</li> <li>• Independent Diabetes Trust</li> <li>• Lipodystrophy UK</li> <li>• Muslim Council of Britain</li> <li>• National Children’s Bureau</li> <li>• Network of Sikh Organisations</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• British Dietetic Association</li> <li>• British Inherited Metabolic Disease Group</li> <li>• British Society for Genetic Medicine</li> <li>• British Society for Human Genetics</li> <li>• British Society for Paediatric Endocrinology and Diabetes</li> <li>• Primary Care Diabetes Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics &amp; Child Health</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Clinical Trials Research Unit</li> <li>• Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Endocrinology</li> <li>• Training Research and Education for Nurses in Diabetes (TREND UK)</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Genetic Testing Network</li> <li>• UK Health Forum</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Great Ormond Street Hospital Metabolic Unit</li> <li>• Department of Endocrinology, University Hospital Birmingham Foundation Trust</li> <li>• NHS England</li> <li>• National Severe Insulin Resistance Service, Addenbrooke's Hospital</li> <li>• Oxford Centre for Diabetes, Endocrinology and Metabolism</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

## **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.